Bacterial resistance and a new antibiotic: Tigecycline;Resistencias bacterianas y un nuevo antibiótico: La tigeciclina

Revista Espanola de Quimioterapia

Volumn 19, Issue 3, 2006, Pages 209-219

  Gobernado, M ^a  

^a HOSPITAL UNIVERSITARIO LA FE   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

AZTREONAM; IMIPENEM; TETRACYCLINE; TIGECYCLINE; VANCOMYCIN;

ACINETOBACTER BAUMANNII; ANTIBIOTIC RESISTANCE; AREA UNDER THE CURVE; BACTERIAL INFECTION; CLINICAL TRIAL; DOSE RESPONSE; DRUG ACTIVITY; ENTEROCOCCUS FAECALIS; ENTEROCOCCUS FAECIUM; ESCHERICHIA COLI; HUMAN; KLEBSIELLA PNEUMONIAE; MAXIMUM ALLOWABLE CONCENTRATION; MEDICAL SOCIETY; META ANALYSIS; NAUSEA; PSEUDOMONAS AERUGINOSA; REVIEW; SIDE EFFECT; STAPHYLOCOCCUS AUREUS; STREPTOCOCCUS PNEUMONIAE; SYSTEMATIC REVIEW; VOMITING;

ANTI-BACTERIAL AGENTS; BACTERIAL INFECTIONS; CLINICAL TRIALS; DRUG RESISTANCE, MULTIPLE, BACTERIAL; HUMANS; MICROBIAL SENSITIVITY TESTS; MINOCYCLINE;

EID: 33750896052     PISSN: 02143429     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (165)

1. Crowcroft, N.S., Catchpole, M. Mortality from methicillin-resistant Staphylococcus aureus in England and Wales: Analysis of death certificates. BMJ 2002; 325: 1390-1391.
2. Levy, S.B. The challenge of antibiotic resistance. Sci Am 1998; 11: 46-53.
3. Cosgrove, S.E., Carmeli, Y. The impact of antimicrobial resistance on health and economic outcomes. Clin Infect Dis 2003; 36: 1433-1437.
4. Plowman, R. The socioeconomic burden of hospital acquired infection. Euro Surveill 2000; 5: 49-50.
5. Abraham, E.P., Chain, E. An enzyme from bacteria able to destroy penicillin. Nature 1940; 146: 837.
6. Jevons, M.P. 'Celbenin'-resistant staphylococci. BMJ 1961; 1: 124-125.
7. Douthawaite, A.H., Trafford, J.A.P. A new synthetic penicillin. BMJ 1960: 687-690.
8. Barber, M. Methicillin resistant staphylococci. J Clin Pathol 1961; 14: 385-393.
9. Bouza, E., Martínez-Beltrán, J. y Grupo de Trabajo para el Estudio de los Estafilococos. Estudio multicéntrico sobre la prevalencia de estafilococos en España. Enferm Infecc Microbiol Clin 1988; 6: 68-79.
10. Cercenado, E., Sánchez-Carrillo, C., Alcalá, L., Bouza, E. y Grupo de Trabajo para el Estudio de los Estafilococos. Situación de la resistencia de Staphylococcus en España. Cuarto Estudio Nacional (1966). Rev Clin Esp 1997; 2 (Supl.): 18-24.
11. Oteo, J., Cruchaga, S., Campos, J., Sáez, J.A., Baquero, F. Antibiotic resistance in blood isolates of Staphylococcus aureus in 31 Spanish hospitals participating in the European Antimicrobial Resistance Surveillance System (2000). Med Clin 2002; 119: 361-365.
12. Cuevas, O., Cercenado, E., Vindel, A. y cols., Spanish Group for the Study of Staphylococcus. Evolution of the antimicrobial resistance of Staphylococcus spp. in Spain: Five nationwide prevalence studies, 1986 to 2002. Antimicrob Agents Chemother 2004; 48: 4240-4245.
13. Hiramatsu, K., Hanaki, H., Ino, T., Yabuta, K., Oguri, T., Tenover, F.C. Methicillin-resistant Staphylococcus aureus clinical strains with reduced vancomycin susceptibility. J Antimicrob Chemother 1997; 40: 135-136.
14. Centers for Disease Control and Prevention. Staphylococcus aureus with reduced susceptibility to vancomycin-Illinois, 1999. MMWR 2000; 48: 1165-1167.
15. Centers for Disease Control and Prevention. Sievert, D.M., Boulton, M.S., Stolman G. y cols. Staphylococcus aureus resistant to vancomycin-United States, 2002. MMWR 2002; 51: 565-567.
16. Kazakova, S.V., Hageman, J.C., Matava, M. y cols. A clone of methicillin-resistant Staphylococcus aureus among professional football players. N Engl J Med 2005; 352: 468-475.
17. Naimi, T.S., LeDell, K.H., Como-Sabetti, K. y cols. Comparison of community- and health care-associated methicillin-resistant Staphylococcus aureus infection. JAMA 2003; 290: 2976-2984.
18. Vandenesch, F., Naimi, T., Enright, M.C. y cols. Community-acquired methicillin-resistant Staphylococcus aureus carrying Panton-Valentine leukocidin genes: Worldwide emergence. Emerg Infect Dis 2003; 9: 978-984.
19. Morin, C.A., Hadler, J.L. Population-based incidence and characteristics of community-onset Staphylococcus aureus infections with bacteremia in 4 metropolitan Connecticut areas, 1998. J Infect Dis 2001; 184: 1029-1034.
20. Moellering, R.C. Jr. The growing menace of community-acquired methicillin-resistant Staphylococcus aureus. Ann Intern Med 2005; 144: 368-370.
21. Hansman, D., Bullen, M.M. A resistant pneumococcus. Lancet 1967; ii: 264-265.
22. Appelbaum, P.C., Koornhof, H.J., Jacobs, M. y cols. Multiple-antibiotic resistance of pneumococci: South Africa. MMWR 1977; 26: 285-286.
23. Appelbaum, P.C., Bhamjee, A., Scragg, J.N. y cols. Streptococcus pneumoniae resistant to penicillin and chloramphenicol. Lancet 1977; ii: 995-997.
24. Jacobs, M.R., Koornhof, H.J., Robins-Browne, R.M. y cols. Emergence of multiply resistant pnemococci. N Engl J Med 1978; 299: 725-740.
25. Appelbaum, P.C. World-wide development of antibiotic resistance in pneumococci. Eur J Clin Microbiol 1987; 6: 367-377.
26. Muñoz, R., Coffey, T.J., Daniels, M. y cols. Intercontinental spred of a multiresistant clone serotype 23F Streptococcus pneumoniae. J Infect Dis 1991; 164: 302-306.
27. Casal, J. Antimicrobial susceptibility of Streptococcus pneumoniae: Serotype distribution of penicillin-resistant strains in Spain. Antimicrob Agents Chemother 1982; 22: 222-225.
28. Gobernado, M., Igual, R., Marco, V. y cols. Infecciones neumocócicas. Epidemiología, serogrupos y resistencias. Med Clin (Barc.) 1983; 80: 54-59.
29. Liñares, J., Garau, J., Domínguez, G., Pérez, J.L. Antibiotic resistance and serotypes of Streptococcus pneumoniae from patients with community adquired pneumococal disease. Antimicrob Agents Chemother 1983; 23: 545-547.
30. Fenoll, A., Martín-Bourgon, C., Muñoz, R. y cols. Serotype distribution and antimicrobial resistance in Streptococcus pneumoniae isolates producing systemic infections in Spain, 1979-1989. Rev Infect Dis 1991; 13: 56-60.
31. Liñares, J., Pallarés, R., Alonso, T. y cols. T. Trends in antimicrobial resistance of clinical isolates of PNE in Bellvitge Hospital, Barcelona, Spain. Clin Infect dis 1992; 15: 99-105.
32. Novak, R., Henriques, B., Charpentioer, E., Normak, S., Tuomanen, E. Emergence of vancomycin tolerance in Streptococcus pneumoniae. Nature 1999; 399: 590-593.
33. McCullers, J.A., English, B.K., Novak, K. Isolation and characterization of vancomycin-tolerant of Streptococcus pneumoniae from the cerebrospinal fluid of a patient who developed recrudescent meningitis. J Infect Dis 2000; 181: 369-373.
34. Henriques, B., Norvak, R., Ortqvist, A., Kallenius, G., Tuomanen, E., Normak, S. Clinical isolates of Streptococcus pneumoniae that exhibited tolerance of vancomycin. Clin Infect Dis 2001; 32: 552-558.
35. Uttley, A.H., Collins, C.H., Naidoo, J. y cols. Vancomycin resistant enterococci. Lancet 1988; i: 57-58.
36. Leclercq, R., Derlot, E., Duval, J. y cols. Plasmid-mediated resistance to vancomycin and teicoplanin in Enterococcus faecium. N Engl J Med 1988; 319: 157-161.
37. Schouten, M.A., Voss, A., Hoogkamp, J.A., European VRE Study Group. Antimicrobial susceptibility patterns of enterococci causing infections in Europe. Antimicrob Agents Chemother 1999; 43: 2542-2546.
38. Sahm, D.F. Antimicrobial resistance among enterococci: A view from US clinical laboratoires. 1st International ASM Conference on Enterococci, Banff, Alberta, Canada 2000.
39. Kauffman, C.A. Therapeutic and preventative options for the management of vancomycin-resistant enterococcal infections. J Antimicrob Chemother 2003; 51 (Suppl. S3): iii23-iii30.
40. Chow, J.W., Donabedian, S.M., Zervos, M.J. Emergence of increased resistance to quinupristin/dalfopristin during therapy for Enterococcus faecium bacteremia. Clin Infect Dis 1997; 24: 90-91.
41. Mutnick, A.H., Enne, V., Jones, R.N. Linezolid resistance since 2001: SENTRY antimicrobial surveillance program. Ann Pharmacother 2003; 37: 769-774.
42. Lautenbach, E., Patel, J.B., Bilker, W.B., Edelstein, P.H., Fishman, N.O. Extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae: Risk factors for infection and impact of resistance on outcomes. Clin Infect Dis 2001; 32: 1162-1171.
43. Neuhauser, M.M., Weinstein, R.A., Rydman, R., Danziger, L.H., Karam, G., Quinn, J.P. Antibiotic resistance among gram-negative bacilli in US intensive care units: Implications for fluoroquinolone use. JAMA 2003; 289: 885-888.
44. Paterson, D., Bonomo, R. Extended-spectrum β-lactamases: A clinical update. Clin Microbiol Rev 2005; 18: 657-686.
45. Sabaté, M., Miró, E., Navarro, F. y cols. Beta-lactamases involved in resistance to broad-spectrum cephalosporins in Escherichia coli and Klebsiella spp. clinical isolates collected between 1994 and 1996, in Barcelona (Spain). J Antimicrob Chemother 2002; 49: 989-997.
46. Miró, E., Del Cuerpo, M., Navarro, F., Sabaté, M., Mirelis, B., Prats, G. Emergence of clinical isolates of Escherichia coli with decreased suceptibility to ceftazidime and synergic effect with co-amoxyclav due to SHV-1 hyperproduction. J Antimicrob Chemother 1998; 42: 535-538.
47. Hernández, J.R., Pascual, A., Cantón, R., Martínez-Martínez, L., Grupo de Estudio de Infección Hospitalaria (GEIH). Escherichia coli y Klebsiella pneumoniae productores de betalaclamasas de espectro extendido en hospitales españoles (Proyecto GEIH-BLEE 2000). Enferm Infecc Microbiol Clin 2003; 21: 77-82.
48. Peña, C., Pujol, M., Ardanuy, C. y cols. Epidemiology and successful control of a large outbreak due to Klebsiella pneumoniae producing extended-spectrum beta-lactamases. Antimicrob Agents Chemother 1998; 42: 53-58.
49. Rodríguez-Baño, J., Navarro, M.D., Romero, L. y cols. A change in the epidemiology and clinical features of infections caused by extended-spectrum beta-lactamase-producing Escherichia coli in nonhospitalized patients. J Clin Microbiol 2004; 42: 1089-1094.
50. Pitout, J., Nordmann, P., Laupland, K., Poirel, L. Emergence of Enterobacteriaceae producing extended-spectrum β-lactamases (ESBLs) in the community. J Antimicrob Chemother 2005; 56: 52-59.
51. Mirelis, B., Navarro, F., Miró, E., Mensa, R.J., Coll, P., Prats, G. Community transmission of extended-spectrum β-lactamase. Emerg Infect Dis 2003; 8: 1024-1025.
52. Gobernado, M. Betalactamasas de espectro extendido en aumento. Rev Esp Quimioterap 2005; 18: 115-117.
53. Sanz-Rodríguez, C.. Baquero, F., Cercenado, E. y cols. Patrones de sensibilidad antimicrobiana de Enterobacteriaceae inducibles y productoras de BLEE causantes de infección intraabdominal en España: Resultados del estudio SMART 2003. VIII Congreso de la Sociedad Española de Quimioterapia, Valencia 2005; Abst. 135.
54. Cisneros, J.M., Reyes M.J., Pachón J. y cols. Bacteremia due to Acinetobacter baumannii: Epidemiology, clinical findings, and prognostic features. Clin Infect Dis 1996; 22: 1026-1032.
55. Bou, G., Cerveró, G., Domínguez, M.A., Quereda, C., Martínez-Beltrán, J. Characterization of nosocomial outbreak caused by a multiresistant Acinetobacter baumannii strain with a carbapenem-hydrolyzing enzyme: High level carbapenem resistance in A. baumannii is not due solely to the presence of β-lactamases. J Clin Microbiol 2000; 38: 3299-3305.
56. Coelho, J., Woodford, N., Turton, J. y cols. Multiresistant Acinetobacter in UK: How big threat? J Hosp Infect 2004; 58: 167-169.
57. Henwood, C.J., Gatward T., Warner, D. y cols. Antibiotic resistance among clinical isolates of Acinetobacter in the UK, and in vitro evaluation on tigecycline (CAR-936). J Antimicrob Chemother 2002; 49: 479-482.
58. Shlaes, D.M., Gerding, D.N., John, F.F. Jr. y cols., Society for Healthcare Epidemiology of American and Infectious Diseases Society of America. Joint Committee on the Prevention of Antimicrobial Resistance: Guidelines for the prevention of antimicrobial resistance in hospitals. Clin Infect Dis 1997; 25: 584-599.
59. IDSA (Infectious Diseases Society of America). Bad bugs, no drugs. As antibiotic discovery stagnates, a public health crisis brews. Disponible en: http://www.idsociety.org/
60. IDSA (Infectious Diseases Society of America). Bad bugs, no drugs executive summary. Antibiotic-resistant bacterial pathogens: Why we are concerned? Disponible en: http://www.idsociety.org/
61. US Congress Office of Technology Assessment. Impacts of antibiotic-resistant bacteria. US Government Printing Office, Washington DC, 2005; Publication No. OTA-H-629.
62. NNIS. National Nosocomial Infections Surveillance (NNIS) System Report, data summary from January 1992 through June 2003, issued August 2003. Am J Infect Control 2003; 31: 481-498.
63. Wisplinghoff, H., Bischoff, T., Tallent, S.M., Seifert, H., Wenzel, R.P., Edmond, M.P. Nosocomial bloodstream infections in US hospitals: Analysis of 24,179 cases from a prospective nationwide surveillance study. Clin Infect Dis 2004; 39: 309-317.
64. Diekema, D.J., BootsMiller, B.J., Vaughn, T.E. y cols. Antimicrobial resistance trends and outbreak frequency in United States Hospitals. Clin Infect Dis 2004; 38: 78-85.
65. Goosens, H., Ferech, M., Stichele, R.V. y cols., for the ESAC group. Outpatients antibiotic use in Europe and association with resistance: a croos-national database study. Lancet 2005; 365: 579-587.
66. Shah, P.M. The need for new therapeutic agents: What is in the pipeline? Clin Microbiol Infect 2005; 11 (Suppl. 3): 36-42.
67. DiMasi, J. A., Hansen, R.W., Grawoky, H.G. The price of innovation. New estimates of drug development cost. J Health Econ 2003; 151-185.
68. Shlaes, D.M. The abandonment of antibacterials. Curr Opin Pharmacol 2003; 3: 470-473.
69. Reichert, J.M. Trends in development and approval times for new therapeutics in the United States. Nat Rev Drug Discov 2003; 695-702.
70. Norrby, S.R., Nord, C.E., Finch, R., European Society of Clinical Microbiology and Infectious Diseases. Lack of development of new antimicrobial drugs: A potential serious threat to public health. Lancet Infect Dis 2004; 5: 115-119.
71. Strahilevitz, J., Rubinstein, E. Novel agents for resistant Gram-positive infections - A review. Int J Infect Dis 2002; 6: S38-S46.
72. Gravestock, M.B. Recent developments in the discovery of novel oxazolidinone antibacterials. Curr Opin Drug Discov Devel 2005; 8: 469-477.
73. Wenzel, R.P. The antibiotic pipeline - Challenges, costs, and values. N Engl J Med 2004: 351: 523-526.
74. Guay, D.R. Oritavancin and tigecycline: Investigational antimicrobials for multidrug-resistant bacteria. Pharmacotherapy 2004; 24: 58-68.
75. Spellberg, B., Powers, J.H., Brass, E.P. y cols. Trends in antimicrobial drugs development. Clin Infect Dis 2004; 31: 1279-1286.
76. Baquero, J.L., Barberán, J. ¿Tendremos nuevos antibióticos? Rev Esp Quimioterap 2006; 19: 113-116.
77. Dowzicky, M., Talbot, G.H., Feger, C., Prokocimer, P., Etienne, J., Leclerq, R. Characterization of isolates associated with emerging resistance to quinupristin/dalfopristin (Synercid) during a worldwide clinical program. Diagn Microbiol Infect Dis 2000; 37: 57-62.
78. Halle, E., Padberg, J., Rosseau, S., Klare, I., Werner, G., Witte, W. Linezolid-resistant Enterococcus faecium and Enterococcus faecalis isolated from a septic patient: Report of first isolates in Germany. Infection 2004; 32: 182-183.
79. Mangili, A., Bica, I., Snydman, D.R., Hamer, D.H. Daptomycin-resistant, methicillin-resistant Staphylococcus aureus bacteremia. Clin Infect Dis 2005; 40: 1058-1060.
80. Meka, V.G., Pillai, S.K., Sakoulas, G. y cols. Linezolid resistance in sequential Staphylococcus aureus isolates associated with a T2500A mutation in the 23S rRNA gene and loss of a single copy of rRNA. J Infect Dis 2004; 190: 311-317.
81. Sabol, K., Patterson, J.E., Lewis, J.S., Owens, A., Cadena, J., Jorgensen, J.H. Emergence of daptomycin resistance in Enterococcus faecium during daptomycin therapy. Antimicrob Agents Chemother 2005; 49: 1664-1665.
82. Potoski, B.A., Adams, J., Clarke, L. y cols. Epidemiological profile of linezolid-resistant coagulase-negative staphylococci. Clin Infect Dis 2006; 43: 165-171.
83. Sum, P.E., Petersen, P. Synthesis and structure-activity relationship of a novel glycylcycline derivatives leading to discovery of GAR-936. Bioorg Med Chem Lett 1999; 9: 1459-1462.
84. Bradford, P.A. Tigecycline: A novel first in class glycylcycline. Clin Microbiol Newslett 2004; 26: 163-168.
85. Chopra, I. Glycylcyclines: Third-generation tetracycline antibiotics. Curr Opin Pharmacol 2001; 1: 464-469.
86. Zhanel, G.G., Homenuik, K., Nichol, K. y cols. The glycylcyclines: A comparative review with the tetracyclines. Drugs 2004; 64: 63-88.
87. Milatovic, D., Schmitz, F.J., Verhoef, J. y cols. Activities of the glycylcycline tigecycline (GAR-936) against 1,924 recent European clinical isolates. Antimicrob Agents Chemother 2003; 47: 400-404.
88. Testa, R., Petersen P.J., Jacobus N.V., Sui P.E., Lee V.L., Tallyn, F.P. In vitro and in vivo antibacterial activities of the glycylcyclines, a new class of semisynthetic tetracyclines. Antimicrob Agents Chemother 1993; 37: 2270-2277.
89. Petersen, P.J., Jacobus, N.V., Weiss, W.J., Sum, P.E., Testa, R.T. In vitro and in vivo antibacterial activities of a novel glycylcycline, the 9-t-butylglycylamido-derivative of minocyclin (GAR-936). Antimicrob Agents Chemother 1999; 43: 738-744.
90. Petersen, P.J., Bradford, P.A., Weiss, W.J., Murphy, T.M., Sum, P.E., Prodan, S.J. In vitro and in vivo activities of tigecycline (GAR-936), daptomycin, and comparative antimicrobial agents against glycopeptide- intermediate Staphylococcus aureus and other resistant gram-positive pathogens. Antimicrob Agents Chemother 2002; 46: 2595-2601.
91. Fritsche, T.R., Kirby, J.T., Jones, R.N. In vitro activity of tigecycline (GAR-936) tested against 11,859 recent clinical isolates associated with community-acquired respiratory tract and gram-positive cutaneous infections. Diagn Microbiol Infect Dis 2004; 49: 201-219.
92. Gales, A.C., Jones, R.N. Antimicrobial activity and spectrum of the new glycylcycline GAR-936 tested against 1,207 recent clinical bacterial isolates. Diagn Microbiol Infect Dis 2000; 36: 19-36.
93. Bouchillon, S., Hoban, D.J., Johnsona, B.M. y cols. In vitro evaluation of tigecycline and comparative agents in 3049 clinical isolates: 2001 to 2002. Diagn Microbiol Infect Dis 2005; 51: 291-295.
94. Morosini, M.I., García-Castillo, M., Coque, M.T. y cols. Antibiotic coresistance in extended-spectrum β-lactamase-producing Enterobacteriaceae and in vitro activity of tigecycline. Antimicrob Agents Chemother 2006; 50: 2695-2699.
95. Betriu, C., Rodríguez-Avial, I., Sánchez, B.A., Gómez, M., Álvarez, J., Picazo, J.J., Spanish Group of Tigecycline. In vitro activity of tigecycline (GAR-936) against recently isolated clinical bacteria in Spain. Antimicrob Agents Chemother 2005; 46: 892-895.
96. Bradford, P.A., Weaver-Sands, T., Petersen, P.J. In vitro activity of tigecycline against isolates from patients enrolled in phase 3 clinical trials of treatment for complicated skin and skin-structure infections and complicated intra-abdominal infections. Clin Infect Dis 2005; 41: S315-S332.
97. Mercier, R.C., Kennedy, C., Meadows, C. Antimicrobial activity of tigecycline (GAR-936) against Enterococcus faecium and Staphylococcus aureus used alone and in combination. Pharmacotherapy 2002; 22: 1517-1523.
98. LaPlante, K.L., Vybak, M.J. Clinical glycopeptide-intermediate staphylococci tested against arbekacin, daptomycin, and tigecycline. Diagn Microbiol Infect Dis 2004; 50: 125-130.
99. Stevens, T., Johnson, B., Johnson, J. y cols. Tigecycline Evaluation Surveillance Trial (T.E.S.T) - In vitro antibacterial activity against selected species of enterobacteriaceae. 44th Interscience Conference on Antimicrobial Agents and Chemotherapy, Washington DC, 2004; Abstr. E-2060.
100. Picazo, J.J., Betriu, C., Gómez, M., Rodríguez-Avial, I., Sánchez, B.A. In vitro activity of tigecycline compared with other antimicrobial agents against recent clinical isolates of methicillin-resistant Staphylococcus aureus. 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago, IL, 2003; Abstr. E-1526.
101. Hoellman, D.B., Pankuch, G.A., Jacobs, M.R., Appelbaum, P.C. Antipneumococcal activities of GAR-936 (a new glycylcycline) compared to those of nine other agents against penicillin-susceptible and resistant pneumococci. Antimicrob Agents Chemother 2000; 44: 1085-1088.
102. Garrison, M.W., Neumiller, J.J., Setter, S.M. Tigecycline: An investigational glycylcycline antimicrobial with activity against resistant Gram-positive organisms. Clin Ther 2005; 27: 12-22.
103. Biendenbach, D.J., Beach, M.L., Jones, R.N. In vitro antimicrobial activity of GAR-936 against antibiotic-resistant gram-positives blood stream infection isolates and strains producing extended-spectrum beta-lactamases. Diag Microbiol Infect Dis 2001; 40: 173-177.
104. Cercenado, E., Cercenado, S., Bouza, E. In vitro activities of tigecycline (GAR-963) and 12 other antimicrobial agents against 90 Eikenella corrodens clinical isolates. Antimicrob Agents Chemother 2003; 47: 264-264.
105. Pachón-Ibáñez, M.E., Jiménez-Mejías, M.E., Pichardo, C., Llanos, A.C., Pachón, J. Activity of tigecycline (GAR-936) against Acinetobacter baumannii strains, including those resistant to imipenemn. Antimicrob Agents Chemother 2004; 48: 4479-4481.
106. Betriu, C., Rodríguez-Avial, I., Sánchez, B.A., Gómez, M., Picazo, J.J. Comparative in vitro activities of tigecycline (GAR-936) and other antimicrobial agents against Stenotrophomonas maltophilia. J Antimicrob Chemother 2002; 50: 758-759.
107. Thamlikitkul, V., Trekulsomboon, S. In vitro activity of tigecycline against Burkholderia pseudomallei and Burkholderia thailandensis. Antimicrob Agents Chemother 2006; 50: 1555-1557.
108. Kenny, G.E., Cartwright, F.D. Susceptibilities of Mycoplasma hominis, M. pneumoniae, and Ureaplasma urealyticum to GAR-396, dalfopristin, dirithromycin, evernimicin, gatifloxacin, linezolid, moxifloxacin, quinupristin-dalfopristin, and telithromycin compared to their susceptibilities to reference macrolides, tetracyclines, and quinolones. Antimicrob Agents Chemother 2001; 45: 2604-2608.
109. Roblin, P.M., Hammerschlag, MR. In vitro activity of GAR-936 against Chlamydia pneumoniae and Chlamydia trachomatis. Int J Antimicrob Agents 2000; 16: 61-63.
110. Edelstein, P.H., Weiss, W.J., Edelstein, M.A. Activities of tigecycline (GAR-936) against Legionella pneumophila in vitro and in guinea pigs with L. pneumophila pneumonia. Antimicrob Agents Chemother 2003; 47: 533-540.
111. Wallace, R.J., Jr., Brown-Elliott, B.A., Crist, C.J., Mann, L., Wilson, R. W. Comparison of the in vitro activity of the glycylcycline tigecycline (formevly GAR-936) with those of tetracycline, minocycline, and doxycycline against isolates of nontuberculous mycobacteria. Antimicrob Agents Chemother 2002; 46: 3164-3167.
112. Rhomberg, P.R., Jones. S.N. In vitro activity of II antimicrobial agents, including gatifloxacin and GAR936, tested against clinical isolates of Mycobacterium marinum. Diagn Microbiol Infect Dis 2002; 42: 145-147.
113. Goldstein, E.J.C., Citron, D.M., Merriam, C.V., Warren, Y., Tyrrell, K. Comparative in vitro activities of GAR-396 against aerobic and anaerobic animal and human bite wound pathogens. Antimicrob Agents Chemother 2000; 44: 2747-2751.
114. Jacobus, N.V., McDermott, L.A., Ruthazer, S., Snydman, D.R. In vitro activities of tigecycline against the Bacteroides fragilis group. Antimicrob Agents Chemother 2004; 48: 1034-1036.
115. Betriu, C., Culebras, E., Gómez, M., Rodríguez-Avial, I., Picazo, J.J. In vitro activity of tigecycline against Bacteroides species. J Antimicrob Chemother 2005; 56: 349-352.
116. Edlund, C., Nord, C.E. In-vitro susceptibility of anaerobic bacteria to GAR-936, a new glycylcycline. Clin Microbiol Infect 2000; 6: 159-163.
117. Van Ogtrop, M.L., Andes, D., Stamstad, T.J. y cols. In vivo pharmacodynamic activities of two glycylcyclines (GAR-936 and WAY 152,288) against various gram-positive and gram-negative bacteria. Antimicrob Agents Chemother 2000; 44: 943-949.
118. Rhomberg, P.R., Jones, R.N. Reproducibility assessment of tigecycline MIC results by broth microdilution methods using commercially prepared dry-form panels. Diagn Microbiol Infect Dis 2005; 52: 67-69.
119. Clinical and Laboratory Standards Institute. Performance standards for antimicrobial susceptibility testing. 15th Informational Supplement. Clinical and Laboratory Standards Institute, Wayne, PA, 2005; Approved Standard, CLSI document M100-S15.
120. EUCAST (European Committee on Antimicrobial Susceptibility Testing). Tigecycline. EUCAST clinical MIC breakpoints. Version 1.2 (2006.06.30). Disponible en: www.eucast.org
121. Hope, R., Warner, M., Ward, M.E. Effect of medium type, age and aeration on the MICs of tigecycline and other tetracyclines. Clin Microbiol Onfect 2005; 11 (Suppl. 2): 246.
122. Bradford, P.A., Petersen, P.J., Young, M., Jones, C.H., Tischler, M., O'Connell, J. Tigecycline MIC testing by broth dilution requires use of fresh medium or addition of the biocatalytic oxygen-reducing agent oxyrase to standardize the test method. Antimicrob Agents Chemother 2005; 49: 3903-3909.
123. Petersen, P.J., Bradford, P.A. Effect of medium age and supplementation with the biocatalytic oxygen-reducing agent oxyrase on in vitro activities of tigecycline against recent clinical isolates. Antimicrob Agents Chemother 2005; 49: 3910-3918.
124. Bergeron, J., Ammirati, M., Danley, D. y cols. Glycylcyclines bind to the high-affinity tetracycline ribosomal binding site and evade Tet(M)- and Tet(O)-mediated ribosomal protection. Antimicrob Agents Chemother 1996; 40: 2226-2228.
125. Bauer, G., Berens, C., Projan, S.J., Hillen, W. Comparison of tetracycline and tigecycline binding to ribosomes mapped by dimethylsulphate and drug-directed Fe2+ cleavage of 16S rRNA. J Antimicrob Chemother 2004; 53: 592-599.
126. Dean, C.R., Visalli, M.A., Projan, S.J., Sum, P.E., Bradford, P.A. Efflux-mediated resistance to tigecycline (GAR-936) in Pseudomonas aeruginosa PAO1. Antimicrob Agents Chemother 2003; 47: 972-978.
127. Yang, W., Moore, I.E. Koteva, K.P. y cols. Test is a flavin-dependent monooxygenase conferring resistance to tetracycline antibiotics. J Biol Chem 2004; 279: 52346-52352.
128. Ruzin, A., Keeney, D., Bradford, P.A. AcrAB efflux pump plays a role in decreased susceptibility to tigecycline in Morganella morganii. Antimicrob Agents Chemother 2005; 49: 791-793.
129. Ruzin, A., Visalli, M.A., Keeney, D., Bradford, P.A. Influence of transcriptional activator RamA on expression of multidrug efflux pump AcrAB and tigecycline susceptibility in Klebsiella pneumoniae. Antimicrob Agents Chemother 2005; 49: 1017-1022.
130. Hirata, T., Saito, A., Nishino, K., Tamura, N., Yamaguchi, A. Effects of efflux transporter genes on susceptibility of Escherichia coli to tigecycline (GAR-936). Antimicrob Agents Chemother 2004; 48: 2179-2184.
131. Visalli, M.A., Murphy, E., Projan, S.J., Bradford, P.A. AcrAB multidrug efflux pump is associated with reduced levels of susceptibility to tigecycline (GAR-936) in Proteus mirabilis. Antimicrob Agents Chemother 2003; 47: 665-669.
132. McAleese, F., Petersen, P., Ruzin, A. y cols. A novel MATE family efflux pump contributes to the reduced susceptibility of laboratory-derived Staphylococcus aureus mutants to tigecycline. Antimicrob Agents Chemother 2005; 49: 1865-1871.
133. Rello, J. Pharmacokinetics, pharmacodynamics, safety and tolerability of tigecycline. J Chemother 2005; 17 (Suppl. 1): 12-22.
134. Stein, G., Craig, W.A. Tigecycline: A critical analysis. Clin Infect Dis 2006; 43: 518-524.
135. Meagher, A.K., Ambrose, P.O., Grasela, T.H., Ellis-Grossen, E.J. The pharmacokinetic and pharmacodynamic profile of tigecycline. Clin Infect Dis 2005; 41 (Suppl. 5): S333-S340.
136. Projan, S.J. Preclinical pharmacology of GAR-936, a novel glycylcycline antibacterial agent. Pharmacotherapy 2000; 20: 219S-223S.
137. Muralidharan, G., Micalizzi, M., Speth, J., Raible, D., Troy, S. Pharmacokinetics of tigecycline after single and multiple doses in healthy subjects. Antimicrob Agents Chemother 2005; 49: 220-229.
138. Sun, H.K., Ong, C.T., Umer A. y cols. Pharmacokinetic profile of tigecycline in serum and skin blister fluid of healthy subjects after multiple intravenous administrations. Antimicrob Agents Chemother 2005; 49: 1629-1632.
139. Conte, J.E. Jr., Golden J.A., Kelly M.G., Zurlinden, E. Steady-state serum and intrapulmonary pharmacokinetics and pharmacodynamics of tigecycline. Int J Antimicrob Agents 2005; 25: 523-529.
140. Ong, C.T., Bablola, C.P., Nightingale, C.H., Nicolau, C.P. Penetration, efflux and intracellular activity of tigecycline in human polymorphonuclear neutrophils (PMNs). J Antimicrob Chemother 2005; 56: 498-501.
141. Murphy, T.M., Deitz, J.M., Petersen, P.J., Mikels, S.M., Weiss, W.J. Therapeutic efficacy of GAR-936, a novel glycylcycline, in a rat model of experimental endocarditis. Antimicrob Agents Chemother 2000; 44: 3022-3027.
142. Lefort, A., Lafaurie, M., Massias, L. y cols. Activity and diffusion of tigecycline (GAR-936) in experimental enterococcal endocarditis. Antimicrob Agents Chemother 2003; 47: 216-222.
143. Nannini, E.C., Pai, S.R., Singh, K.V., Murray, B.E. Activity of tigecycline (GAR-936), a novel glycylcycline, against Enterococci in the mouse peritonitis model. Antimicrob Agents Chemother 2003; 47: 529-532.
144. Yin, L.Y., Lazzarini, L., Li, F., Stevens, C.M., Calhoun, J.H. Comparative evaluation of tigecycline and vancomycin, with and without rifampicin, in the treatment of methicillin-resistant Staphylococcus aureus experimental osteomyelitis in a rabbit model. J Antimicrob Chemother 2005; 55: 995-1002.
145. Labthavikul, P., Petersen, P.J., Bradford, P.A. In vitro activity of tigecycline against Staphylococcus epidermidis growing in an adherent-cell biofilm model. Antimicrob Agents Chemother 2003; 47: 3967-3969.
146. Murray, J., Wilson, S., Klein, S., Yellin, A., Loh, E. The clinical response to tigecycline in the treatment of complicated intra-abdominal infections in hospitalized patients, a phase 2 clinical trial. 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago, IL, 2003; Abstr. L-739.
147. Dartois, N., for the Tigecycline 305 cSSSI Study Group. Results of a phase 3, double-blind, safety and efficacy study comparing tigecycline with vancomycin/aztreonam to treat complicated skin and skin structure infections. 44th Interscience Conference on Antimicrobial Agents and Chemotherapy, Washington, DC, 2004; Abstr. L-986.
148. Dartois, N., Gioud-Paquet, M., Ellis-Grosse, E.J., Loh, E., for the Tigecycline 306 Study Group. Tigecycline vs. imipenem/cilastatin for treatment of complicated intra-abdominal infections. 44th Interscience Conference on Antimicrobial Agents and Chemotherapy, Washington, DC, 2004; Abstr. L-992c.
149. Yu, H., Mallick, R., Weber, D.J. Duration of antibiotic treatment in hospitalized patients with complicated skin and skin structure infections (cSSSI): Findings from a clinical study comparing tigecycline and vancomycin/aztreonam. International Society for Pharmacoeconomics and Outcomes Research, 10th Annual Meeting, Washington, DC, 2005; Poster PIN3.
150. Mallick, R., Yu, H., Weber, D.J. Length of stay in patients hospitalized in the United States with complicated skin and skin structure infections (cSSSI): Findings from pooled clinical studies comparing tigecycline and vancomycin/aztreonam. Infectious Disease Society of America, 43rd Annual Meeting, San Francisco, CA, 2005; Abstr. 367.
151. Postier, R.G., Green, S.L., Klein, S.R., Ellis-Grosse, E.J., Loh, E. Results of a multicenter, randomized, open-label efficacy and safety study of two doses of tigecycline for complicated skin and skin-structure infections in hospitalized patients. Clin Ther 2004; 26: 704-714.
152. Breedt, J., Teras, J., Gardovskis, J. y cols. Safety and efficacy of tigecycline in treatment of skin and skin structure infections: Results of a double-blind phase 3 comparison study with vancomycin-aztreonam. Antimicrob Agents Chemother 2005; 49: 4658-4666.
153. Sacchadinand, S., Penn, R.L., Embil, J.M. y cols. Efficacy and safety of tigecycline monotherapy compared with vancomycin plus aztreonam in patients with complicated skin and skin structure infections: Results from a phase 3, randomized, double-blind trial. Int J Infect Dis 2005; 9: 251-261.
154. Ellis-Grosse, E.J., Loh, E. Tigecycline compared with imipenem/cilastatin in the treatment of complicated intra-abdominal infections. 15th European Congress of Clinical Microbiology and Infectious Diseases, Copenhagen, Denmark, 2005; Abstr. P1317.
155. Fomin, P., Beuran, M., Gradauskas, A. y cols., 306 Study Group. Tigecycline is efficacious in the treatment of complicated intra-abdominal infections. Int J Surg 2005; 3: 35-47.
156. Oliva, M.E., Rekha, A., Yellin, A. y cols., 301 Study Group. A multicenter trial of the efficacy and safety of tigecycline versus imipenem/cilastatin in patients with complicated intra-abdominal infections. Infect Dis 2005; 5: 88.
157. Wilson, P. Endemic, highly resistant Acinetobacter in the intensive care unit - Is tigecycline the answer? Clin Microbiol Infect 2004; 10 (Suppl. 3): 247 (Abstr. P938).
158. Meagher, A., Cirincione, B., Piedmonte, M., Troy, S., Ambrose, P.G. Pharmacokinetics of tigecycline in healthy adult volunteers and in subjects with renal impairment. 14th European Congress of Clinical Microbiology and Infectious Diseases, Prague, Czech Republic, 2004; Abstr. P1023.
159. Troy, S.M., Muralidharan, G., Micalizzi, M., Mojavarian, P., Salacinski, L., Raible, D. The effects of renal disease on the pharmacokinetics of tigecycline (GAR-936). 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago, IL, 2003; Abstr. A-22.
160. Muralidharan, G., Fruncillo R.J., Micalizzi M., Raible D.G., Troy, S.M. Effects of age and sex on single-dose pharmacokinetics of tigecycline in healthy subjects. Antimicrob Agents Chemother 2005; 49: 1656-1659.
161. Zimmerman, J.J., Harper, D., Matschke, K., Speth, J., Raible, D.G., Fruncillo, R.J. Pharmacokinetics and pharmacodynamics of tigecycline and digoxin coadministered to healthy men. 44th Interscience Conference on Antimicrobial Agents and Chemotherapy, Washington, DC, 2004; Abstr. A-460.
162. Dunn, C.J. Tigecycline: An evidence-based review of its antibacterial activity and effectiveness in complicated skin and soft tissue and intraabdominal infections. Core Evid 2006; 1: 181-194.
163. Nathwani, D. Tigecycline: Clinical evidence and formulary positioning. Int J Antimicrob Agents 2005; 25: 1851-1892.
164. Livermore, D.M. Tigecycline: What is it, and where should it be use? J Antimicrob Chemother 2005; 56: 611-614.
165. Noskin, G. A. Tigecycline: A new glycylcycline for treatment of serious infections. Clin Infect Dis 2005; 41: S303-S314.